Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience

被引：0

作者：

Bose, Subhadeep ^{[1
]}

Khaja, Mujtaba Syed ^{[1
]}

Siva, Asha ^{[1
]}

Wilson, Paula ^{[1
]}

Grist, Helen ^{[1
]}

Murukesh, Nishanth ^{[1
]}

机构：

[1] Worcestershire Acute Hosp NHS Trust, Worcester, W Midlands, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21091

引用

页数：1

共 50 条

[41] Real-World Data of Osimertinib in Patients with Metastatic EGFRm plus NSCLC who Progressed on First-Line EGFR TKIs
Ma, J.
Tan, S. H.
Yin, D.
Tran, A.
Tan, D.
Ang, M.
Takano, A.
Lim, K. H. T.
Kanesvaran, R.
Jain, A.
Rajasekaran, T.
Tan, E.
Lim, D. W.
Ng, Q. S.
Tan, W.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S627 - S628
[42] REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC NSCLC AFTER RECEIVING FIRST-LINE PEMBROLIZUMAB WITH PEMETREXED/PLATINUM CHEMOTHERAPY IN THE US ONCOLOGY NETWORK
Goldschmidt, Jerome
Annavarapu, Srinivas
Venkatasetty, Divea
Santorelli, Melissa
Burke, Thomas
Pennell, Nathan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A974 - A975
[43] First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN
Hou, X.
Zhou, C.
Wu, G.
Lin, W.
Xie, Z.
Zhang, H.
Yi, J.
Peng, Z.
Yin, L.
Ma, C.
Chen, L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S318 - S318
[44] Number needed to treat analysis applied to pembrolizumab plus chemotherapy for first-line treatment of non-squamous non-small cell lung cancer
Paladini, Luciano
Pereira da Veiga, Cassia Rita
Cerqueira, Erica
Haas, Laura Chabrol
Abadi, Marcia Datz
Baldotto, Clarissa Serodio
JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1185 - 1193
[45] PEMETREXED IN COMBINATION WITH CISPLATIN IN THE FIRST-LINE TREATMENT OF NON-SQUAMOUS NSCLC: CZECH EXPERIENCE WITH 233 PATIENTS
Skrickova, Jana
Bortlicek, Zdenek
Hejduk, Karel
Pesek, Milos
Kolek, Vitezslav
Koubkova, Leona
Roubec, Jaromir
Tomiskova, Marcela
Satankova, Monika
Povolna, Zdenka
Havel, Libor
Coupkova, Helena
Salajka, Frantisek
Hrnciarik, Michal
Zemanova, Milada
Sixtova, Dimka
Cernovska, Marketa
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S864 - S864
[46] Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience
Ranganathan, Sanjana
Riveros, Carlos
Xu, Jiaqiong
Hu, Siqi
Geng, Michael
Huang, Emily
Melchiode, Zachary
Zhang, Jun
Efstathiou, Eleni
Chan, Keith Syson
Wallis, Christopher J. D.
Sonpavde, Guru
Satkunasivam, Raj
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (09) : 291e13 - 291e25
[47] Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Umpawan, N.
Termsinsuk, P.
Kaosombatwattana, U.
Akewanlop, C.
Korphaisarn, K.
ANNALS OF ONCOLOGY, 2023, 34 : S919 - S920
[48] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
Liu, Qiao
Zhou, Zhen
Luo, Xia
Yi, Lidan
Peng, Liubao
Wan, Xiaomin
Tan, Chongqing
Zeng, Xiaohui
FRONTIERS IN PHARMACOLOGY, 2022, 12
[49] Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma: A single centre experience exploring effects of dose-reduction
Tokaca, N.
O'Brien, M.
Bhosle, J.
Yousaf, N.
Kumar, R.
Popat, S.
Walder, D.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S89 - S90
[50] Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
Yang, Zhenyun
Wu, Weijie
Hu, Zhiwen
Fu, Yizhen
Hu, Zili
Pan, Yangxun
Wang, Juncheng
Chen, Jinbin
Zhou, Zhongguo
Zhang, Yaojun
Chen, Minshan
Hu, Dandan
FRONTIERS IN IMMUNOLOGY, 2024, 15

← 1 2 3 4 5 →